Radiopharm Theranostics Limited (AU:RAD) has released an update.
Radiopharm Theranostics has upped its stake in Radiopharm Ventures to 75%, signaling confidence as their leading B7H3 monoclonal antibody candidate nears the end of preclinical studies with a Phase I trial expected in early 2025. This move, bolstered by an additional $4 million investment, aims to advance cancer treatment radiopharmaceuticals, alongside two other promising preclinical assets targeting solid tumors.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.
